|
Patent landscape, scope, and claims summary: |
United States Patent 10,759,866 (US10,759,866): Critical claim analysis and US patent estate map for CHO-produced anti-CD20 antibodies via pre-harvest air sparging to protect disulfides
US10,759,866 claims a process for producing therapeutic anti-CD20 monoclonal antibodies in CHO cells, with a defined pre-harvest air sparging step intended to prevent reduction of antibody disulfide bonds by maintaining dissolved oxygen (dO2) above specified thresholds. The enforceable core is the combination of (i) CHO recombinant production, (ii) pre-harvest sparging of the pre-harvest cell culture fluid with air, and (iii) continuation of sparging until dO2 is at least 10% (and dependent claim ranges up to “at least 30%” and “between 100% saturated to 30% saturated with air”), plus dependent scope by scale and specific CD20 binders (rituximab, ocrelizumab). This is a narrower, process-adaptation patent rather than a composition-of-matter patent, with typical validity and infringement leverage tied to whether an accused process actually performs pre-harvest air sparging and whether it achieves the stated oxygen/dissolved-oxygen targets during the pre-harvest window.
What is the inventive concept of US 10,759,866 and what do its claims actually cover?
Short answer: The patent protects a CHO manufacturing process that adds an air-sparging step to the pre-harvest cell culture fluid to keep dissolved oxygen high enough to avoid disulfide bond reduction in the secreted anti-CD20 IgG during downstream processing.
Claim 1 dissection: required elements that must all be present
Independent claim 1 has five material pillars; each is likely to be litigated.
-
Method context
- “A method for producing an antibody”
- “expressing the antibody in a CHO recombinant host cell culture”
- “following a production phase of the cell culture”
-
Targeted pre-harvest unit operation
- “sparging the pre-harvest cell culture fluid of the recombinant host cell with air”
- “to prevent reduction of a disulfide bond in the antibody during processing”
-
Oxygen-driven endpoint
- “air sparging is continued until” dissolved oxygen in the pre-harvest fluid is at least 10%
-
Therapeutic antibody identity
-
Delivery target class
- the antibody is a “therapeutic monoclonal antibody” (not a fragment, not a diagnostic reagent)
Dependent claims narrow endpoints or scope
- Claim 2: endpoint is “at least 30% saturated with air.”
- Claim 3: endpoint is “between 100% saturated to 30% saturated with air.”
- Claim 4: endpoint is “dO2 at least 30%.”
- Claim 5: production scale “greater than 5,000 L.”
- Claims 6-7: downstream coupling by “preparing the harvested cell culture fluid” and “recovering/purifying” the antibody.
- Claim 8: CD20 binder is rituximab.
- Claim 9: CD20 binder is ocrelizumab.
Practical meaning: where infringement will concentrate
From an infringement perspective, the hardest-to-litigate or most evidence-heavy components are typically:
- whether the accused process performs air sparging of the pre-harvest cell culture fluid (not just general aeration during production),
- whether the “pre-harvest” stage is defined similarly,
- whether the company hits the specific dO2 or air saturation targets (≥10% and/or ≥30%),
- whether the accused step is claimed as having the functional purpose “to prevent reduction of a disulfide bond” (functional language can be a factual fight tied to mechanism and outcomes).
Which parts of US10,759,866 are likely strongest for enforcement versus vulnerable on validity?
Short answer: The oxygen-threshold and pre-harvest sparging combination is the likely strongest claim anchor. Vulnerabilities are (i) whether similar oxygen management and redox control were already disclosed in CHO anti-CD20 or other IgG processes, and (ii) whether the functional “prevent reduction of disulfide bonds” limitation is sufficiently supported and tied to the oxygen endpoint.
Likely strongest claim anchors
-
Pre-harvest timing and operation
- “following a production phase”
- “sparging the pre-harvest cell culture fluid”
- This timing constraint differentiates from routine aeration in the production reactor.
-
Quantified endpoint
- “dO2 … at least 10%”
- Dependent claims push to “at least 30%,” or “between 100% and 30% saturated.”
-
Defined target product class
- anti-CD20 monoclonals, with dependent explicit drug embodiments for rituximab and ocrelizumab.
Likely validity pressure points
-
Anticipation or obviousness risk from generic CHO redox control
- CHO IgG manufacturing has long addressed oxidative stress, disulfide formation/reduction risk, and redox environment management.
- If prior art discloses oxygenation or sparging approaches during the pre-harvest or harvest window to protect disulfides, US10,759,866 could face anticipation or obviousness.
-
“Air sparging” could be read broadly
- Prior processes using gas sparging, sparging with oxygen-enriched air, or maintaining headspace/medium oxygen might be argued as equivalent.
- If the spec does not tightly define air sparging hardware, duration, and measurement method for dO2, the “continued until” oxygen endpoint becomes even more critical.
-
Functional limitation coupling
- “to prevent reduction of a disulfide bond … during processing” introduces a mechanism/outcome limitation.
- In some disputes, courts treat functional language as limiting even if the claim is process-defined, but the evidentiary record then becomes central: did oxygenation measurably prevent reduction, and is that prevention linked to the claimed endpoint?
What prior art themes typically map onto this claim set (disulfides, redox, oxygenation, CHO harvest windows)?
Short answer: The claim will be evaluated against prior disclosures on (i) oxygen control during CHO cultivation and harvest preparation, (ii) prevention of disulfide reduction in downstream handling, and (iii) sparging or oxygenation strategies applied to harvest fluid or hold tanks.
Common prior-art overlap themes likely argued by challengers
- Oxygen management in CHO production and harvest conditioning
- Aeration during production is standard; the claim’s emphasis is pre-harvest conditioning.
- Redox state control to protect thiol-disulfide equilibrium
- IgG stability in processing is tied to reduction/oxidation balance.
- Maintenance of dissolved oxygen in hold vessels
- Some manufacturers manage dissolved oxygen in hold tanks to avoid degradation or aggregation.
Common gaps challengers will seek
- No prior disclosure that specifically ties pre-harvest air sparging to achieving dO2 thresholds (≥10% and ≥30%) with an explicit anti-CD20 therapeutic context.
- No prior disclosure that uses the same unit operation at the same timing (post-production phase, pre-harvest fluid).
- No prior disclosure that measures dO2 in a directly comparable way (“%” vs absolute mg/L; saturation definition differences).
How does US10,759,866 claim oxygen endpoints (dO2 vs air saturation), and why does that matter for infringement?
Short answer: Claim 1 uses a dO2 endpoint “at least 10%,” while dependent claims use air saturation percent and dissolved oxygen percent. These are distinct metrics that can create claim-construction and measurement disputes.
Claim 1: dO2 is at least 10%
- The key phrase is “amount of dissolved oxygen (dO2) … is at least 10%.”
- “%” implies a relative measurement, typically percent saturation relative to air at the given conditions or oxygen solubility.
Claim 2 and 3: air saturation percent thresholds
- “at least 30% saturated with air” (claim 2)
- “between 100% saturated to 30% saturated with air” (claim 3)
Claim 4: dO2 at least 30%
- Parallel to claim 1 but higher threshold.
Litigation relevance
- Accused manufacturers will often have oxygen control logs in mg/L, DO probes calibrated to air saturation, and different regimes before harvest.
- If a competitor reports DO in absolute terms, the translation to “%” and to the probe’s calibration basis can be determinative.
- If a process applies sparging but does not maintain the claimed “continued until” endpoint during the relevant pre-harvest interval, infringement risk declines.
Does US10,759,866 cover rituximab and ocrelizumab specifically, and how should that affect market targeting?
Short answer: The claims include dependent embodiments for rituximab and ocrelizumab, but the independent claim is drafted by product functional identity (anti-CD20 therapeutic monoclonals). That means the estate can be asserted against processes for other anti-CD20s if the accused product binds CD20 and meets the process features.
Practical coverage mapping
- Claim 8 (rituximab) is a dependent narrowing limitation; it strengthens targeting for rituximab manufacturing processes with the same pre-harvest oxygenation step.
- Claim 9 (ocrelizumab) similarly targets ocrelizumab.
- Because independent claim 1 only requires “binds to CD20,” the strongest enforcement leverage depends on whether those specific products are actually in the asserted defendant’s portfolio.
Strategy note for enforcement/clearance
- For licensing or freedom-to-operate, the key question is not whether the defendant makes rituximab or ocrelizumab, but whether it performs the claimed pre-harvest sparging with the oxygen endpoint for any therapeutic anti-CD20 monoclonal.
What scale limitation exists in US10,759,866 and how can it be used in design-arounds?
Short answer: Claim 5 limits to “scale greater than 5,000 L,” which can be a significant carve-out if a process operates at smaller production scales.
Scale-as-a-claim element
- The limitation appears only in claim 5.
- If a process is asserted under claim 1, claim 5 is irrelevant.
- If asserted under claim 5 specifically, the manufacturer can use scale facts (bioreactor volume, train configuration, campaign mode) to dispute meeting “greater than 5,000 L.”
What is the patent’s likely regulatory and manufacturing positioning: does it behave like a method-of-use, method-of-manufacture, or process patent?
Short answer: It is a classic method-of-manufacture process patent tied to manufacturing operations. It is not a direct “use” claim, and it targets production process choices that can exist regardless of FDA labeling.
Orange Book relevance (expectation for this claim type)
- Process-only patents typically do not appear in the Orange Book for small-molecule drugs, but for biologics the “Orange Book” concept maps to the Biosimilars/Biologics and BLA reference product framework.
- If the patent is listed for a reference product under the BLA framework, it would provide a basis for patent use in the biosimilar context; otherwise, it remains enforceable as an issued US patent but does not automatically attach to FDA licensure listing mechanisms.
Practical implication
- Even when not listed, method patents are still enforceable against infringing manufacturing. The big question is how the patent is deployed in FDA patent listing or settlement strategies.
What litigation and licensing scenarios are most likely for a process patent like US10,759,866?
Short answer: The most likely disputes are between brand manufacturers and companies developing biosimilars or manufacturing alternative processes, with settlement incentives tied to whether the accused processes include pre-harvest sparging with the claimed oxygen thresholds.
Likely defendant profiles
- Biosimilar developers targeting anti-CD20 products.
- Contract manufacturing organizations (CMOs) supporting multiple biologics where process recipes can be compared through discovery.
- Manufacturers of bioengineered anti-CD20s with different formulation strategies but similar upstream and harvest-handling oxygen control.
Settlement levers
- Modifying pre-harvest conditioning steps (sparging method, duration, oxygen endpoint targets).
- Switching gas composition (air vs oxygen-enriched gas vs nitrogen balancing).
- Changing hold tank designs and dissolved oxygen measurement/profiling to fall outside thresholds.
- Timing changes defining when “pre-harvest” begins relative to sampling and hold.
Which claim terms will be central to claim construction (infringement/validity) for US10,759,866?
Short answer: “pre-harvest cell culture fluid,” “sparging … with air,” “continued until,” and the numeric oxygen metrics (dO2 % and air saturation %) will drive both infringement and validity arguments.
High-frequency litigation terms
- “pre-harvest cell culture fluid”
- “sparging … with air”
- “continued until”
- “dissolved oxygen (dO2) … at least 10%”
- “at least 30% saturated with air”
- “between 100% saturated to 30% saturated”
- “to prevent reduction of a disulfide bond … during processing”
Evidence most likely to matter
- DO sensor calibration records and measurement logs.
- Batch record documentation describing when sparging begins and ends.
- Dosing history of gas flow rates and sparging duration.
- Assay results for disulfide reduction indicators, if the mechanism is contested.
How does US10,759,866 compare with typical anti-CD20 manufacturing IP: is this upstream, downstream, or stability-focused?
Short answer: It is upstream-to-harvest conditioning focused, with downstream relevance through disulfide stability during processing.
Classification by operation
- Upstream: CHO expression culture.
- Boundary step: “following a production phase.”
- Critical step: pre-harvest air sparging of harvested/harvest-bound fluid.
- Downstream link: recovery and purification, plus an asserted stability outcome (prevent disulfide reduction).
Competitive implication
- Companies can face IP exposure even if they use different purification resins, filtration schemes, or buffers, so long as the pre-harvest oxygenation step is within the claims.
How many claims does US10,759,866 have and what does the dependency structure imply for claim coverage breadth?
Short answer: The patent has at least 9 claims based on the provided claim set. Dependency concentrates extra scope in oxygen endpoints (10% vs 30% ranges), scale (>5,000 L), and specific product embodiments (rituximab, ocrelizumab).
Dependency structure as a coverage map
- Claim 1: broad anchor for all anti-CD20 therapeutic mAbs made in CHO with pre-harvest air sparging to dO2 ≥10%.
- Claims 2-4: narrower oxygen targets.
- Claim 5: additional narrowness for large-scale manufacturing.
- Claims 6-7: procedural add-ons for preparing and purifying harvested fluid.
- Claims 8-9: add-on specificity for rituximab and ocrelizumab.
What generic entry risks exist for anti-CD20 products under a process patent like US10,759,866?
Short answer: Entry risk is less about “generics” and more about biosimilar manufacturing and process design. The biggest risk is that biosimilar developers adopt pre-harvest sparging recipes to protect disulfides and may inadvertently match the oxygen endpoints.
Risk drivers
- Use of CHO for expression (explicitly required).
- Adoption of an air sparging step on the pre-harvest fluid.
- Operating conditions that keep DO at or above 10% (or ≥30%) during the claimed window.
Design-around levers
- Reduce oxygen endpoint below 10% (if scientifically acceptable for stability).
- Remove or replace air sparging at pre-harvest (use alternative redox control).
- Change from air sparging to other gas strategies that do not meet the “with air” limitation or do not achieve the same oxygen endpoints.
Key Takeaways
- US10,759,866 is a CHO method-of-manufacture patent focused on pre-harvest air sparging to keep dissolved oxygen high and avoid disulfide bond reduction in secreted anti-CD20 monoclonals.
- The independent claim’s enforceable core is the combination of CHO production, pre-harvest air sparging, and maintaining dO2 ≥10% during the sparging interval.
- Dependent claims tighten exposure via dO2/air saturation thresholds (≥30% and 100% to 30%), large-scale operation >5,000 L, and specific CD20 antibodies including rituximab and ocrelizumab.
- Infringement and validity will pivot on technical evidence: oxygen measurement basis, timing definition of “pre-harvest”, whether gas is truly “air,” and whether the accused process hits the claimed “continued until” endpoint.
- For biosimilar and process-change strategies, the main risk is adopting pre-harvest oxygenation steps that closely track the patented oxygen thresholds, even if downstream purification differs.
FAQs
1) If a manufacturer aerates during the CHO production phase, does that infringe US10,759,866?
Not by the face of the claim. The patent requires sparging the pre-harvest cell culture fluid after the production phase, with sparging continued until the claimed DO/air saturation endpoint is reached.
2) Can a process infringe if it uses oxygen-enriched air rather than air?
The claim is specific to sparging “with air.” Whether oxygen-enriched gas counts depends on claim construction of “air” and the evidence of gas composition; the on-record framing in the claims points to the defendant needing to avoid matching the “with air” element.
3) Does US10,759,866 protect downstream purification steps?
It includes dependent claims covering “preparing” harvested fluid and “recovering/purifying” the antibody, but the critical inventive step is the pre-harvest sparging oxygen endpoint.
4) If the product binds CD20 but is not rituximab or ocrelizumab, is it still covered?
Yes for claim 1, because claim 1 requires only that the therapeutic monoclonal antibody binds CD20. Rituximab and ocrelizumab are dependent embodiments.
5) Is the scale limitation (>5,000 L) required for infringement?
No for claim 1. The scale limitation appears in claim 5 only; a plaintiff could still assert claim 1 without proving the >5,000 L feature.
References (APA)
- United States Patent US10,759,866. Claims 1-9 as provided in the user prompt.
More… ↓
⤷ Start Trial
|
